Company intelligence / Profile preview
Alector
South San Francisco, California, United Statesalector.com ↗
- Ownership
- Public · ALEC
- Employees
- ~100
- Development stage
- Phase 3
01
Overview
Alector has advanced its lead candidate AL001 to a global Phase 3 trial for FTD-GRN. AL101 is in Phase 2 for Alzheimer’s disease. Preclinical programs target additional neurodegenerative diseases. The company leverages immunology and neurology insights to develop first-in-class therapies that modulate immune activity in the brain. Early clinical data have shown normalization of progranulin levels and promising safety/biomarker results.
- Therapeutic areas
- Neurology
- Modalities
- Antibody therapeutics (monoclonal antibodies)protein replacement therapies
- Industry
- Biotech
02
Drug pipeline
22 assets21 more assets in the full pipeline.
03
Partnerships
GSK for development of AL101Adimab for R&D of additional antibodiesFormer partnership with AbbVie on Alzheimer's program ended July 2022Johnson & Johnson Innovation Center collaboration on early research targets
04
Financials
- Market cap
- $233.4M
- Total revenue
- $21M
- Enterprise value
- $40.2M
Beyond the preview
Go deeper on Alector.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alector.